The association between heart failure and incident cancer in women: an analysis of the Women's Health Initiative.
Cancer
Cardio-oncology
Heart failure
Prospective cohort
Risk
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
28
04
2021
received:
05
01
2021
accepted:
29
04
2021
pubmed:
2
5
2021
medline:
1
4
2022
entrez:
1
5
2021
Statut:
ppublish
Résumé
There is conflicting evidence whether heart failure (HF) is a risk factor for incident cancer. Despite population-based cohorts demonstrating this association, an analysis of the Physician's Health Study found no association in a cohort of mostly healthy males. We investigated the association of HF with incident cancer among a large cohort of post-menopausal women. A prospective cohort study of 146 817 post-menopausal women age 50 to 79 years enrolled in the Women's Health Initiative from 1993-1998, and followed through 2015. The primary exposure was adjudicated incident HF diagnosis, including preserved and reduced ejection fraction in a sub-cohort. The primary outcome was adjudicated incident total and site-specific cancers. Hazard ratios were calculated using multivariable-adjusted Cox proportional hazard regression models. Over a median follow-up of 8.4 years, 3272 and 17 474 women developed HF and cancer, respectively. HF developed in 235 women prior to cancer. HF was associated with subsequent incident cancer [hazard ratio (HR) 1.28, 95% confidence interval (CI) 1.11-1.48]. Associations were observed for obesity-related cancers (HR 1.24, 95% CI 1.02-1.51), as well as lung and colorectal cancers (HR 1.58, 95% CI 1.09-2.30 and HR 1.52, 95% CI 1.02-2.27, respectively). HF with preserved ejection fraction (HR 1.34, 95% CI 1.06-1.67), but not HF reduced ejection fraction (HR 0.99, 95% CI 0.74-1.34), was associated with total cancer. Heart failure was associated with an increase in cancer diagnoses in post-menopausal women. This association was strongest for lung cancer. Further research is needed to appreciate the underlying mechanisms responsible for this association.
Identifiants
pubmed: 33932263
doi: 10.1002/ejhf.2207
pmc: PMC8591611
mid: NIHMS1754254
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1712-1721Subventions
Organisme : NHLBI NIH HHS
ID : HHSN268201600002C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600018C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600004C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600001C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600003C
Pays : United States
Organisme : NINR NIH HHS
ID : F31 NR018588
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 European Society of Cardiology.
Références
Ann Epidemiol. 2003 Oct;13(9 Suppl):S122-8
pubmed: 14575944
J Am Coll Cardiol. 2004 Apr 21;43(8):1432-8
pubmed: 15093880
Circulation. 2011 May 10;123(18):2006-13; discussion 2014
pubmed: 21555723
Control Clin Trials. 1998 Feb;19(1):61-109
pubmed: 9492970
Circulation. 2019 Mar 5;139(10):1289-1299
pubmed: 30586730
Circ Res. 2013 Aug 30;113(6):646-59
pubmed: 23989710
Obes Rev. 2013 Aug;14(8):665-78
pubmed: 23615120
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
JAMA. 2004 Jul 21;292(3):344-50
pubmed: 15265849
J Am Coll Cardiol. 2016 Jul 19;68(3):265-271
pubmed: 27417004
Circ Heart Fail. 2016 Oct;9(10):
pubmed: 27682440
Int J Cardiol. 2019 Sep 1;290:106-112
pubmed: 31104823
J Intern Med. 2001 Jun;249(6):519-26
pubmed: 11422658
Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1532-44
pubmed: 20501755
Circulation. 2018 Aug 14;138(7):678-691
pubmed: 29459363
J Am Coll Cardiol. 2018 Apr 10;71(14):1501-1510
pubmed: 29622155
Eur J Heart Fail. 2016 Mar;18(3):260-6
pubmed: 26751260
Circulation. 2016 Mar 15;133(11):1104-14
pubmed: 26976915
Ann Epidemiol. 2003 Oct;13(9 Suppl):S18-77
pubmed: 14575939
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
J Am Coll Cardiol. 2012 Mar 13;59(11):998-1005
pubmed: 22402071
JACC CardioOncol. 2019 Dec 17;1(2):196-205
pubmed: 34396183
IARC Monogr Eval Carcinog Risks Hum. 2010;96:3-1383
pubmed: 21735939
Lancet. 2016 Oct 8;388(10053):1659-1724
pubmed: 27733284
Circulation. 2000 Sep 5;102(10):1126-31
pubmed: 10973841
J Natl Cancer Inst. 2015 Mar 10;107(2):
pubmed: 25757865
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
JAMA Cardiol. 2019 Jan 1;4(1):25-33
pubmed: 30566180
Eur Heart J. 2008 Feb;29(3):339-47
pubmed: 18156618
Hypertens Res. 2017 Sep;40(9):831-836
pubmed: 28381869
N Engl J Med. 1989 Jul 20;321(3):129-35
pubmed: 2664509
N Engl J Med. 2017 Jul 13;377(2):111-121
pubmed: 28636844
J Am Coll Cardiol. 2013 Sep 3;62(10):881-6
pubmed: 23810869
JAMA. 2006 Nov 8;296(18):2209-16
pubmed: 17090767
Eur J Heart Fail. 2018 May;20(5):879-887
pubmed: 29464808
Circulation. 2009 Jun 23;119(24):3070-7
pubmed: 19506115
N Engl J Med. 2014 Dec 25;371(26):2488-98
pubmed: 25426837
Circ Heart Fail. 2008 Jul;1(2):91-7
pubmed: 19300532
Lancet. 2017 Oct 21;390(10105):1833-1842
pubmed: 28855077
JAMA Cardiol. 2018 Oct 1;3(10):1011-1019
pubmed: 30140928